Xierkang

Chongqing Xierkang Company is a high-tech enterprise specializing in the research and development, production, and clinical research of blood purification equipment. Since its establishment in 2009, Xierkang Company has been committed to the research, development, and manufacturing of hemoperfusion devices, with products covering six major fields including resin adsorption columns, resin charcoal adsorption columns, bilirubin adsorption columns, low-density lipoprotein adsorption columns, endotoxin adsorption columns, and specific adsorption columns.
The company maintains long-term cooperative relationships with multiple research institutes such as the Chinese PLA General Hospital, the Academy of Military Medical Sciences, Harbin Medical University, Jilin University, the Institute of Molecular Biology of Nankai University in Tianjin, the School of Environmental and Biological Science and Technology of Dalian University of Technology, the Third Military Medical University, and the College of Bioengineering of Chongqing University.
The company has an experienced team, with all management personnel holding bachelor's degrees or above, among whom: the proportion of senior professional titles is 6%, the proportion of intermediate professional titles is 20%, and there are several personnel with junior professional titles, making it a high-quality, highly educated, and youthful team.
The company is committed to developing hemoperfusion devices with internationally advanced levels, possesses all core technologies for manufacturing hemoperfusion devices, from raw material synthesis, special equipment manufacturing, and canister design, and owns completely independent intellectual property rights. It has applied for 21 national patents, filling some technical gaps in this field in China, achieving import substitution of hemoperfusion devices, enhancing China's international competitiveness in this industry, and marking that China has achieved synchronization and integration with the world in the technical field of blood purification equipment.
The company has clear property rights, sound corporate governance, a complete organizational structure, and a robust management system. It has taken the lead in passing ISO13485 quality system certification and GMP certification for medical devices, and is a high-tech enterprise.
After the company received its first round of venture capital investment in 2010 (Chongqing Science and Technology Venture Capital Investment Co., Ltd. under the Ministry of Science and Technology), in 2012, it successively received capital injections from two well-known domestic venture capital firms (Shenzhen Capital Group and Hongtu Biology Investment Company), indicating that the company's products and technologies have been recognized and affirmed by renowned institutions.
With the corporate spirit of "courage to advance, courage to strive, courage to innovate, courage to climb, and never-ending," the company continuously pioneers and strives to achieve a 50% market share for charcoal-type perfusion devices.
At present, the company has a great need for talent reserves and is widely recruiting talents. Adhering to the principle of appointing people on merit, it hopes to find various talents who are willing to share joys and hardships with the company and develop together.
A high starting point in life, starting from Xierkang!
Welcome to visit the company website: *
Special notes:
Xierkang Company:
A place where you can entrust the rest of your life........
1. The company has been established for 10 years, with considerable sales prospects;
2. The products are included in the medical insurance catalog, and their quality has surpassed that of foreign products;
3. Three well-known domestic venture capital companies have injected capital and taken equity stakes;
4. There are only 5 companies of the same type nationwide;
5. For outstanding performers, the company will provide entrepreneurial advisor positions or equity incentives......